US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lakewood-Amedex Biotherapeutics (Direct Listing)

0.7822

-0.0098-1.24%

Post-market: 0.81980.0376+4.81%17:31 EDT

Volume:118.05K

Turnover:94.29K

Market Cap:1.85M

PE:-0.25

High:0.8211

Open:0.7931

Low:0.7800

Close:0.7920

52wk High:98.20

52wk Low:0.7610

Shares:2.37M

Float Shares:1.39M

Volume Ratio:0.06

T/O Rate:8.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1006

EPS(LYR):-8.3987

ROE:-402.84%

ROA:-139.40%

PB:0.43

PE(LYR):-0.09

Loading ...

Overview Company News Filings

Lakewood-Amedex Says Lead Bisphosphocin Candidate Nu-3 Posts Phase 2a Diabetic Foot Ulcer Trial Data in Q1 2027

Lakewood-Amedex Biotherapeutics - Bisphosphocin Nu-3 Phase 2a Trial Topline Data Expected Q1 2027

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

THOMSON REUTERS

Lakewood-Amedex CEO Presents Nu-3 Preclinical Poster at IDWeek

Lakewood-Amedex Biotherapeutics Holds Annual Shareholder Meeting

Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up 20% Today?

Lakewood-Amedex Biotherapeutics reports positive MIC data from Nu-3 study

Lakewood-Amedex Reports Positive MIC Data for Nu-3 Against Infected Diabetic Foot Ulcer Isolates

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics Lists on NASDAQ Capital Market Under LABT Ticker

Lakewood-Amedex Biotherapeutics - Prospectus Filed for Resale of up to 4,512,400 Shares of Common Stock by Certain Selling Stockholder - SEC Filing

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics Announces Irb Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics CEO Presents at H.C. Wainwright Global Investment Conference

Lakewood-Amedex Q2 FY26 Net Loss Widens to $3.77 Million; R&D Expense More than Doubled to $503,020

Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting

Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting

Lakewood-amedex Biotherapeutics Flags New Press Release Available on Nu-3 Resistance Data

Lakewood-Amedex announces preclinical data from Phase 2a clinical trial

Lakewood-amedex Biotherapeutics Reports Release Available on Nu-3 Gel Preclinical Safety Data

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/LABT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":0.7822,"timestamp":1791576000000,"preClose":0.792,"halted":0,"volume":118052,"hourTrading":{"tag":"盘后","latestPrice":0.8198,"preClose":0.7822,"latestTime":"17:31 EDT","volume":2702,"amount":2123.2740214,"timestamp":1791581483481,"change":0.0376,"changeRate":0.04807,"amplitude":0.063411},"delay":0,"changeRate":-0.012373737373737412,"floatShares":1387907,"shares":2369700,"eps":-3.1005669,"marketStatus":"Post-Mkt","change":-0.0098,"latestTime":"10-09 17:37:52 EDT","open":0.7931,"high":0.8211,"low":0.78,"amount":94285.08311683999,"amplitude":0.051894,"askPrice":0.82,"askSize":5000,"bidPrice":0.7315,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.1005669,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791590400000},"marketStatusCode":4,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":0.792,"preHourTrading":{"tag":"盘前","latestPrice":0.8211,"preClose":0.792,"latestTime":"09:26 EDT","volume":11276,"amount":9121.55624696,"timestamp":1791552370575,"change":0.0291,"changeRate":0.036742,"amplitude":0.081818},"postHourTrading":{"tag":"盘后","latestPrice":0.8198,"preClose":0.7822,"latestTime":"17:31 EDT","volume":2702,"amount":2123.2740214,"timestamp":1791581483481,"change":0.0376,"changeRate":0.04807,"amplitude":0.063411},"volumeRatio":0.06368},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","floatShares":1387907,"roa":"-139.40%","roe":"-402.84%","lyrEps":-8.39872,"volumeRatio":0.06368,"shares":2369700,"dividePrice":0,"high":0.8211,"amplitude":0.051894,"preClose":0.792,"low":0.78,"week52Low":0.761,"pbRate":"0.43","week52High":98.2,"institutionHeld":0,"latestPrice":0.7822,"committee":-0.960784,"eps":-3.1005669,"divideRate":0,"volume":118052,"delay":0,"ttmEps":-3.1005669,"open":0.7931,"prevYearClose":80,"prevWeekClose":0.9326,"prevMonthClose":0.9553,"prevQuarterClose":0.9553,"fiveDayClose":0.9326,"twentyDayClose":2.22,"sixtyDayClose":1.85},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-06-22","symbol":"LABT","defaultRemindTime":1782135000000,"type":"split","dateTimestamp":1782100800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LABT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LABT","date":"2026-10-08","current":-0.252276,"percent":1,"low":-12.282138,"twenty":-2.641925,"median":-0.815635,"eighty":-0.661169,"high":-0.274079,"avg":-2.078377,"sd":2.935315,"marketCap":2013760},"quantilePoints":[{"date":"2026-05-08","current":-12.282138,"twenty":-12.192813,"median":-11.891342,"eighty":-11.604759,"marketCap":47257207},{"date":"2026-05-15","current":-7.294845,"twenty":-12.043939,"median":-11.649421,"eighty":-11.314454,"marketCap":28067917},{"date":"2026-05-22","current":-2.865088,"twenty":-11.850402,"median":-11.258627,"eighty":-3.412052,"marketCap":11023817},{"date":"2026-05-29","current":-2.716586,"twenty":-11.716415,"median":-6.438817,"eighty":-2.758568,"marketCap":10452435},{"date":"2026-06-05","current":-2.512255,"twenty":-11.604759,"median":-3.225364,"eighty":-2.559299,"marketCap":9666247},{"date":"2026-06-12","current":-2.69016,"twenty":-11.537766,"median":-2.813168,"eighty":-2.512255,"marketCap":10350760},{"date":"2026-06-18","current":-2.241304,"twenty":-11.42611,"median":-2.776507,"eighty":-2.512255,"marketCap":8623724},{"date":"2026-06-26","current":-1.276597,"twenty":-10.242559,"median":-2.72924,"eighty":-2.388094,"marketCap":4911883},{"date":"2026-07-02","current":-1.116845,"twenty":-7.294845,"median":-2.69016,"eighty":-1.477578,"marketCap":4725718},{"date":"2026-07-10","current":-0.893476,"twenty":-5.58279,"median":-2.580737,"eighty":-1.276597,"marketCap":3780575},{"date":"2026-07-17","current":-0.62611,"twenty":-3.536511,"median":-2.512255,"eighty":-1.062695,"marketCap":2649266},{"date":"2026-07-24","current":-1.03562,"twenty":-3.225364,"median":-2.41344,"eighty":-0.92732,"marketCap":4382030},{"date":"2026-07-31","current":-0.653185,"twenty":-2.937143,"median":-2.34533,"eighty":-0.879262,"marketCap":2763829},{"date":"2026-08-07","current":-0.754716,"twenty":-2.857942,"median":-1.477578,"eighty":-0.80819,"marketCap":3193440},{"date":"2026-08-14","current":-0.78856,"twenty":-2.830251,"median":-1.371504,"eighty":-0.793975,"marketCap":3336643},{"date":"2026-08-21","current":-0.706322,"twenty":-2.806803,"median":-1.276597,"eighty":-0.779084,"marketCap":5189616},{"date":"2026-08-28","current":-0.803079,"twenty":-2.760875,"median":-1.18284,"eighty":-0.754039,"marketCap":5900523},{"date":"2026-09-04","current":-0.612791,"twenty":-2.735567,"median":-1.116845,"eighty":-0.749426,"marketCap":4502407},{"date":"2026-09-11","current":-0.661169,"twenty":-2.730282,"median":-1.03562,"eighty":-0.735555,"marketCap":4857860},{"date":"2026-09-18","current":-0.59989,"twenty":-2.721648,"median":-0.925628,"eighty":-0.713886,"marketCap":4407619},{"date":"2026-09-25","current":-0.588602,"twenty":-2.70073,"median":-0.89016,"eighty":-0.694712,"marketCap":4324680},{"date":"2026-10-02","current":-0.299977,"twenty":-2.666042,"median":-0.854556,"eighty":-0.672485,"marketCap":2204046},{"date":"2026-10-08","current":-0.274079,"twenty":-2.641925,"median":-0.815635,"eighty":-0.661169,"marketCap":2013760}],"updateTime":1791581872687},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673090265","title":"Lakewood-Amedex Says Lead Bisphosphocin Candidate Nu-3 Posts Phase 2a Diabetic Foot Ulcer Trial Data in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673090265","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673090265?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:02","pubTimestamp":1791374562,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex says lead Bisphosphocin candidate Nu-3 posts Phase 2a diabetic foot ulcer trial data in Q1 2027Lakewood-Amedex Biotherapeutics reported positive preclinical results for Bisphosphocin c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL1rsVLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673902310","title":"Lakewood-Amedex Biotherapeutics - Bisphosphocin Nu-3 Phase 2a Trial Topline Data Expected Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673902310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673902310?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:02","pubTimestamp":1791374545,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T111:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673287090","title":"Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds","url":"https://stock-news.laohu8.com/highlight/detail?id=2673287090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673287090?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:02","pubTimestamp":1791374545,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T111:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672724754","title":"Lakewood-Amedex CEO Presents Nu-3 Preclinical Poster at IDWeek","url":"https://stock-news.laohu8.com/highlight/detail?id=2672724754","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672724754?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:04","pubTimestamp":1790856262,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex CEO presents Nu-3 preclinical poster at IDWeekLakewood-Amedex will attend the Maxim Growth Summit on Oct. 13-14, 2026 in New York City.CEO Kelvin Cooper will present at the ThinkEquity","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDLHfmcJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671729218","title":"Lakewood-Amedex Biotherapeutics Holds Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2671729218","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671729218?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:01","pubTimestamp":1790676108,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics holds annual shareholder meetingLakewood-Amedex Biotherapeutics held its annual shareholder meeting on Sept. 22, 2026.Shareholders backed an articles amendment raising ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL20d8hV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670538152","title":"Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up 20% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2670538152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670538152?lang=en_us&edition=fundamental","pubTime":"2026-09-28 21:47","pubTimestamp":1790603250,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics stock rallied on Monday after it announced new data for its lead candidate.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-penny-stock-lakewood-amedex-biotherapeutics-labt-up-20-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-penny-stock-lakewood-amedex-biotherapeutics-labt-up-20-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670232718","title":"Lakewood-Amedex Biotherapeutics reports positive MIC data from Nu-3 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2670232718","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670232718?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:11","pubTimestamp":1790597462,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics (LABT) announced positive Minimum Inhibitory Concentration data from recent clinical isolates for its lead clinical...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-reports-positive-mic-data-from-nu-3-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-reports-positive-mic-data-from-nu-3-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670643232","title":"Lakewood-Amedex Reports Positive MIC Data for Nu-3 Against Infected Diabetic Foot Ulcer Isolates","url":"https://stock-news.laohu8.com/highlight/detail?id=2670643232","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670643232?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:05","pubTimestamp":1790597135,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex reports positive MIC data for Nu-3 against infected diabetic foot ulcer isolatesLakewood-Amedex Biotherapeutics reported positive lab data for Nu-3 against recent bacterial samples fro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDLbsZ7gm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670346232","title":"Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2670346232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670346232?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:02","pubTimestamp":1790596943,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45K0BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669046065","title":"Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2669046065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669046065?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:02","pubTimestamp":1790251320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA4B3QWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669816365","title":"Lakewood-Amedex Biotherapeutics Lists on NASDAQ Capital Market Under LABT Ticker","url":"https://stock-news.laohu8.com/highlight/detail?id=2669816365","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669816365?lang=en_us&edition=fundamental","pubTime":"2026-09-21 20:04","pubTimestamp":1789992286,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics lists on Nasdaq Capital Market under LABT tickerLakewood-Amedex Biotherapeutics shifted its stock listing to the Nasdaq Capital Market under ticker LABT on April 23, 20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL2LLlTl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668751499","title":"Lakewood-Amedex Biotherapeutics - Prospectus Filed for Resale of up to 4,512,400 Shares of Common Stock by Certain Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2668751499","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668751499?lang=en_us&edition=fundamental","pubTime":"2026-09-19 05:32","pubTimestamp":1789767168,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nFWN45A0KA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923218","title":"Lakewood-Amedex Biotherapeutics Announces Irb Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923218?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:14","pubTimestamp":1789733645,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUABR3JPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320968","title":"Lakewood-Amedex Biotherapeutics CEO Presents at H.C. Wainwright Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320968","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320968?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:07","pubTimestamp":1788869252,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics CEO presents at H.C. Wainwright Global Investment ConferenceLakewood-Amedex Biotherapeutics will present virtually at the H.C. Wainwright 28th Annual Global Investment ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDLb7XN0v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659110010","title":"Lakewood-Amedex Q2 FY26 Net Loss Widens to $3.77 Million; R&D Expense More than Doubled to $503,020","url":"https://stock-news.laohu8.com/highlight/detail?id=2659110010","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659110010?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:08","pubTimestamp":1786702114,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Q2 FY26 net loss widens to $3.77 million; R&D expense more than doubled to $503,020Lakewood-Amedex posted a net loss of $3.77 million for the quarter ended June 30, 2026, widening from the prior-year period.Operating loss widened to $3.79 million as total operating expenses climbed to $3.79 million.Research and development spending more than doubled to $503,020, driven by higher manufacturing, regulatory and clinical planning for Nu-3 Phase 2a.General and administrative costs jumped to $3.29 million, mainly due to $2.4 million in noncash professional services tied to stock issuance.Series C Convertible Preferred Stock private placement raised about $6.8 million net; common stock began trading on Nasdaq Capital Market on April 23.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2kZSYf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658954040","title":"Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2658954040","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658954040?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:14","pubTimestamp":1786396498,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics announces annual shareholder meetingLakewood-Amedex Biotherapeutics will hold its annual shareholder meeting virtually on Sept. 22, 2026.Shareholders will vote to elect","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL8pvPMK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655939386","title":"Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2655939386","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655939386?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:33","pubTimestamp":1785443614,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics announces annual shareholder meetingLakewood-Amedex Biotherapeutics will hold its annual stockholder meeting virtually on September 22, 2026.Shareholders will vote on e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL4nbJ9R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653577357","title":"Lakewood-amedex Biotherapeutics Flags New Press Release Available on Nu-3 Resistance Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2653577357","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653577357?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:04","pubTimestamp":1784721865,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics flags new press release available on Nu-3 resistance dataLakewood-Amedex published a July 22, 2026 release highlighting new resistance data for Nu-3, its Phase 2-ready ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL5F7T3W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651946871","title":"Lakewood-Amedex announces preclinical data from Phase 2a clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651946871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651946871?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:10","pubTimestamp":1784117436,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics (LABT) announced robust preclinical safety data that establishes a strong foundation for clinical dose selection in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-announces-preclinical-data-from-phase-2a-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-announces-preclinical-data-from-phase-2a-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4139","LABT","HYLG","GDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651446850","title":"Lakewood-amedex Biotherapeutics Reports Release Available on Nu-3 Gel Preclinical Safety Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2651446850","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651446850?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:05","pubTimestamp":1784117146,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics reports release available on Nu-3 gel preclinical safety dataLakewood-Amedex Biotherapeutics posted preclinical safety data supporting dose selection for a planned Phas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL2m8FqM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}]}}